Reuters logo
BRIEF-Newron Pharmaceuticals says FDA approves Xadago for Parkinson's disease patients
March 21, 2017 / 6:46 PM / 6 months ago

BRIEF-Newron Pharmaceuticals says FDA approves Xadago for Parkinson's disease patients

March 21 (Reuters) - Newron Pharmaceuticals SpA:

* FDA approves Xadago (safinamide) for parkinson’s disease (PD) patients

* Announced FDA approved use of Xadago for treatment of Parkinson’s disease as add-on therapy to Levodopa/Carbidopa

* Will now accelerate U.S. launch preparations for Xadago Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below